FAQs about our Team
From 2008.igem.org
(New page: <html xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns="http://www.w3.org/TR/REC-html40"> <head> <meta name=Title content="Frequentl...) |
|||
Line 1: | Line 1: | ||
- | <html xmlns:o="urn:schemas-microsoft-com:office:office" | + | <html xmlns:v="urn:schemas-microsoft-com:vml" |
+ | xmlns:o="urn:schemas-microsoft-com:office:office" | ||
xmlns:w="urn:schemas-microsoft-com:office:word" | xmlns:w="urn:schemas-microsoft-com:office:word" | ||
xmlns="http://www.w3.org/TR/REC-html40"> | xmlns="http://www.w3.org/TR/REC-html40"> | ||
Line 19: | Line 20: | ||
<o:LastAuthor>Andrew Horwitz</o:LastAuthor> | <o:LastAuthor>Andrew Horwitz</o:LastAuthor> | ||
<o:Revision>2</o:Revision> | <o:Revision>2</o:Revision> | ||
- | <o:Created>2008-10-23T00: | + | <o:TotalTime>0</o:TotalTime> |
- | <o:LastSaved>2008-10-23T00: | + | <o:Created>2008-10-23T00:12:00Z</o:Created> |
+ | <o:LastSaved>2008-10-23T00:12:00Z</o:LastSaved> | ||
<o:Pages>1</o:Pages> | <o:Pages>1</o:Pages> | ||
- | <o:Words> | + | <o:Words>315</o:Words> |
- | <o:Characters> | + | <o:Characters>1801</o:Characters> |
<o:Company>UCSF</o:Company> | <o:Company>UCSF</o:Company> | ||
- | <o:Lines> | + | <o:Lines>15</o:Lines> |
<o:Paragraphs>3</o:Paragraphs> | <o:Paragraphs>3</o:Paragraphs> | ||
- | <o:CharactersWithSpaces> | + | <o:CharactersWithSpaces>2211</o:CharactersWithSpaces> |
<o:Version>11.1280</o:Version> | <o:Version>11.1280</o:Version> | ||
</o:DocumentProperties> | </o:DocumentProperties> | ||
Line 54: | Line 56: | ||
{font-family:Arial; | {font-family:Arial; | ||
panose-1:0 2 11 6 4 2 2 2 2 2; | panose-1:0 2 11 6 4 2 2 2 2 2; | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
mso-font-charset:0; | mso-font-charset:0; | ||
mso-generic-font-family:auto; | mso-generic-font-family:auto; | ||
Line 70: | Line 66: | ||
margin-bottom:.0001pt; | margin-bottom:.0001pt; | ||
mso-pagination:widow-orphan; | mso-pagination:widow-orphan; | ||
+ | font-size:12.0pt; | ||
+ | font-family:"Times New Roman";} | ||
+ | p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2 | ||
+ | {mso-style-update:auto; | ||
+ | margin-top:0in; | ||
+ | margin-right:0in; | ||
+ | margin-bottom:0in; | ||
+ | margin-left:.5in; | ||
+ | margin-bottom:.0001pt; | ||
+ | text-indent:-.25in; | ||
+ | mso-pagination:widow-orphan; | ||
+ | mso-list:l0 level1 lfo10; | ||
+ | tab-stops:list .5in; | ||
font-size:12.0pt; | font-size:12.0pt; | ||
font-family:"Times New Roman";} | font-family:"Times New Roman";} | ||
Line 86: | Line 95: | ||
/* List Definitions */ | /* List Definitions */ | ||
@list l0 | @list l0 | ||
+ | {mso-list-id:-125; | ||
+ | mso-list-type:simple; | ||
+ | mso-list-template-ids:-1508585756;} | ||
+ | @list l0:level1 | ||
+ | {mso-level-number-format:bullet; | ||
+ | mso-level-style-link:"List Bullet 2"; | ||
+ | mso-level-text:\F0B7; | ||
+ | mso-level-tab-stop:.5in; | ||
+ | mso-level-number-position:left; | ||
+ | text-indent:-.25in; | ||
+ | font-family:Symbol;} | ||
+ | @list l1 | ||
{mso-list-id:52774932; | {mso-list-id:52774932; | ||
mso-list-type:hybrid; | mso-list-type:hybrid; | ||
mso-list-template-ids:989912902 67698703 67698689 67698689 67698703 67698713 67698715 67698703 67698713 67698715;} | mso-list-template-ids:989912902 67698703 67698689 67698689 67698703 67698713 67698715 67698703 67698713 67698715;} | ||
- | @list | + | @list l1:level2 |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
{mso-level-number-format:bullet; | {mso-level-number-format:bullet; | ||
mso-level-text:\F0B7; | mso-level-text:\F0B7; | ||
Line 100: | Line 117: | ||
text-indent:-.25in; | text-indent:-.25in; | ||
font-family:Symbol;} | font-family:Symbol;} | ||
- | @list | + | @list l1:level3 |
{mso-level-number-format:bullet; | {mso-level-number-format:bullet; | ||
mso-level-text:\F0B7; | mso-level-text:\F0B7; | ||
Line 108: | Line 125: | ||
text-indent:-.25in; | text-indent:-.25in; | ||
font-family:Symbol;} | font-family:Symbol;} | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
@list l2 | @list l2 | ||
{mso-list-id:524756907; | {mso-list-id:524756907; | ||
Line 175: | Line 143: | ||
font-family:Symbol;} | font-family:Symbol;} | ||
@list l3 | @list l3 | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
{mso-list-id:1669675019; | {mso-list-id:1669675019; | ||
mso-list-type:hybrid; | mso-list-type:hybrid; | ||
mso-list-template-ids:1454386800 67698689 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;} | mso-list-template-ids:1454386800 67698689 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;} | ||
- | @list | + | @list l3:level1 |
{mso-level-number-format:bullet; | {mso-level-number-format:bullet; | ||
mso-level-text:\F0B7; | mso-level-text:\F0B7; | ||
Line 360: | Line 160: | ||
--> | --> | ||
</style> | </style> | ||
+ | <!--[if gte mso 9]><xml> | ||
+ | <o:shapedefaults v:ext="edit" spidmax="1027"/> | ||
+ | </xml><![endif]--><!--[if gte mso 9]><xml> | ||
+ | <o:shapelayout v:ext="edit"> | ||
+ | <o:idmap v:ext="edit" data="1"/> | ||
+ | </o:shapelayout></xml><![endif]--> | ||
</head> | </head> | ||
Line 370: | Line 176: | ||
is control of gene expression by chromatin different from control by transcription | is control of gene expression by chromatin different from control by transcription | ||
factors (and what are its advantages)?<o:p></o:p></b></span></p> | factors (and what are its advantages)?<o:p></o:p></b></span></p> | ||
- | |||
- | |||
<p class=MsoNormal><span style='font-family:Arial'><b>A. <span | <p class=MsoNormal><span style='font-family:Arial'><b>A. <span | ||
Line 377: | Line 181: | ||
is a completely different level of gene expression control.<o:p></o:p></b></span></p> | is a completely different level of gene expression control.<o:p></o:p></b></span></p> | ||
- | < | + | <p class=MsoListBullet2 style='margin-left:1.0in;mso-list:l1 level2 lfo3; |
- | + | tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | |
- | + | style='font:7.0pt "Times New Roman"'> | |
- | + | </span></span><![endif]>Dominant over transcription factors (resistant to | |
- | + | noise).</p> | |
- | + | ||
- | + | <p class=MsoListBullet2 style='margin-left:1.0in;mso-list:l1 level2 lfo3; | |
- | + | tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | |
- | + | style='font:7.0pt "Times New Roman"'> | |
- | + | </span></span><![endif]>Regional – silences domains, not individual genes | |
- | + | (reduces the engineering required for regulation of complex multi-gene | |
- | + | systems).</p> | |
- | + | ||
- | + | <p class=MsoListBullet2 style='margin-left:1.0in;mso-list:l1 level2 lfo3; | |
- | + | tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | |
- | + | style='font:7.0pt "Times New Roman"'> | |
- | + | </span></span><![endif]>Memory–Alteration in gene expression lasts for | |
- | + | multiple generations (epigenetic control).</p> | |
+ | |||
+ | <p class=MsoListBullet2 style='margin-left:1.0in;mso-list:l1 level2 lfo3; | ||
+ | tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | ||
+ | style='font:7.0pt "Times New Roman"'> | ||
+ | </span></span><![endif]>Intrinsically bistable, i.e. all-or-none expression | ||
+ | (increases parameter space over which circuits are predicted to be stable).</p> | ||
<p class=MsoNormal><span style='font-family:Arial'><![if !supportEmptyParas]> <![endif]><o:p></o:p></span></p> | <p class=MsoNormal><span style='font-family:Arial'><![if !supportEmptyParas]> <![endif]><o:p></o:p></span></p> | ||
Line 404: | Line 214: | ||
applications could this type of synthetic chromatin control system be used for?<o:p></o:p></b></span></p> | applications could this type of synthetic chromatin control system be used for?<o:p></o:p></b></span></p> | ||
- | <p class=MsoNormal style=' | + | <p class=MsoNormal><span style='font-family:Arial'><b>A. <span |
+ | style='mso-tab-count:1'> </span>To | ||
+ | stably and permanently switch cells between different states characterized by significant differences in gene expression (i.e. cellular differentiation).<o:p></o:p></b></span></p> | ||
- | <p class= | + | <p class=MsoListBullet2 style='margin-left:1.0in;mso-list:l2 level2 lfo5; |
- | style='font-family: | + | tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span |
- | + | style='font:7.0pt "Times New Roman"'> | |
- | + | </span></span><![endif]>In bio-production–for coordinated switching | |
+ | between a growth phase and a production phase.</p> | ||
- | <p class= | + | <p class=MsoListBullet2 style='margin-left:1.0in;mso-list:l3 level1 lfo7; |
tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | ||
style='font:7.0pt "Times New Roman"'> | style='font:7.0pt "Times New Roman"'> | ||
- | </span></span><![endif] | + | </span></span><![endif]>In bio-production–to differentiate a clonal |
- | + | population of cells into a distribution of subtypes that function cooperatively | |
+ | (“factory” with different specialized “workers”).</p> | ||
- | <p class= | + | <p class=MsoListBullet2 style='margin-left:1.0in;mso-list:l1 level2 lfo3; |
tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | ||
style='font:7.0pt "Times New Roman"'> | style='font:7.0pt "Times New Roman"'> | ||
- | </span></span><![endif]> | + | </span></span><![endif]>To reprogram cell fate in a highly specific manner |
- | + | (e.g. stem cell engineering, correction of epigenetic abnormalities in cancer | |
- | + | cells).</p> | |
- | < | + | <p class=MsoListBullet2 style='margin-left:1.0in;mso-list:l1 level2 lfo3; |
- | + | tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | |
- | + | style='font:7.0pt "Times New Roman"'> | |
- | + | </span></span><![endif]>To create cells with highly digital computational | |
- | + | capabilities.</p> | |
- | + | ||
- | + | <p class=MsoListBullet2 style='margin-left:1.0in;mso-list:l1 level2 lfo3; | |
- | + | tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | |
- | + | style='font:7.0pt "Times New Roman"'> | |
- | + | </span></span><![endif]>To study chromatin spreading mechanism in a | |
- | + | quantitative and controlled way.</p> | |
- | + | ||
- | + | ||
- | + | ||
<p class=MsoNormal style='margin-left:.25in'><span style='font-family:Arial'><![if !supportEmptyParas]> <![endif]><o:p></o:p></span></p> | <p class=MsoNormal style='margin-left:.25in'><span style='font-family:Arial'><![if !supportEmptyParas]> <![endif]><o:p></o:p></span></p> | ||
Line 443: | Line 254: | ||
<p class=MsoNormal style='margin-left:.25in'><span style='font-family:Arial'><![if !supportEmptyParas]> <![endif]><o:p></o:p></span></p> | <p class=MsoNormal style='margin-left:.25in'><span style='font-family:Arial'><![if !supportEmptyParas]> <![endif]><o:p></o:p></span></p> | ||
- | < | + | <p class=MsoNormal><span style='font-family:Arial'><b>Q. <span |
- | + | style='mso-tab-count:1'> </span>Could | |
- | + | this type of yeast synthetic chromatin control system be utilized in other cell | |
- | + | types, including mammalian cells?<o:p></o:p></b></span></p> | |
- | + | ||
- | + | <p class=MsoNormal><span style='font-family:Arial'><b>A. <span | |
- | + | style='mso-tab-count:1'> </span>Yes, | |
- | + | the approach should be transferable.<o:p></o:p></b></span></p> | |
- | + | ||
- | + | <p class=MsoListBullet2 style='margin-left:1.0in;mso-list:l1 level2 lfo3; | |
- | + | tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | |
- | + | style='font:7.0pt "Times New Roman"'> | |
- | + | </span></span><![endif]>Core elements of this system are: initiator, covalent | |
- | + | mark, spreading (polymerization).</p> | |
- | + | ||
- | + | <p class=MsoListBullet2 style='margin-left:1.0in;mso-list:l1 level2 lfo3; | |
- | + | tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | |
- | + | style='font:7.0pt "Times New Roman"'> | |
- | + | </span></span><![endif]>In <i>S. cerevisiae</i><span style='font-style:normal'>, | |
- | + | covalent mark is deacetylation–we use an initiator (LexA-Sir2) that when | |
- | + | localized deacetylates adjacent histones.<span style="mso-spacerun: yes"> | |
- | + | </span>This leads to further recruitment of Sir2, which propagates the mark | |
- | + | outward. Deacetylated chromatin adopts a “closed” conformation. </span></p> | |
+ | |||
+ | <p class=MsoListBullet2 style='margin-left:1.0in;mso-list:l1 level2 lfo3; | ||
+ | tab-stops:list 1.0in'><![if !supportLists]><span style='font-family:Symbol'>·<span | ||
+ | style='font:7.0pt "Times New Roman"'> | ||
+ | </span></span><![endif]>For higher eukaryotes, from <i>S. pombe</i><span | ||
+ | style='font-style:normal'> to human, the covalent mark is methylation, | ||
+ | initiator is a histone methyltransferase. But in principle, a similar system | ||
+ | should work.<span style="mso-spacerun: yes"> </span>Same logical design, | ||
+ | with different catalytic functions propagating spread.</span></p> | ||
<p class=MsoNormal><span style='font-family:Arial'><span style="mso-spacerun: | <p class=MsoNormal><span style='font-family:Arial'><span style="mso-spacerun: | ||
Line 475: | Line 295: | ||
</html> | </html> | ||
+ | |||
Revision as of 00:16, 23 October 2008
Q. How
is control of gene expression by chromatin different from control by transcription
factors (and what are its advantages)?
A. Chromatin
is a completely different level of gene expression control.
· Dominant over transcription factors (resistant to noise).
· Regional – silences domains, not individual genes (reduces the engineering required for regulation of complex multi-gene systems).
· Memory–Alteration in gene expression lasts for multiple generations (epigenetic control).
· Intrinsically bistable, i.e. all-or-none expression (increases parameter space over which circuits are predicted to be stable).
Q. What
applications could this type of synthetic chromatin control system be used for?
A. To
stably and permanently switch cells between different states characterized by significant differences in gene expression (i.e. cellular differentiation).
· In bio-production–for coordinated switching between a growth phase and a production phase.
· In bio-production–to differentiate a clonal population of cells into a distribution of subtypes that function cooperatively (“factory” with different specialized “workers”).
· To reprogram cell fate in a highly specific manner (e.g. stem cell engineering, correction of epigenetic abnormalities in cancer cells).
· To create cells with highly digital computational capabilities.
· To study chromatin spreading mechanism in a quantitative and controlled way.
Q. Could
this type of yeast synthetic chromatin control system be utilized in other cell
types, including mammalian cells?
A. Yes,
the approach should be transferable.
· Core elements of this system are: initiator, covalent mark, spreading (polymerization).
· In S. cerevisiae, covalent mark is deacetylation–we use an initiator (LexA-Sir2) that when localized deacetylates adjacent histones. This leads to further recruitment of Sir2, which propagates the mark outward. Deacetylated chromatin adopts a “closed” conformation.
· For higher eukaryotes, from S. pombe to human, the covalent mark is methylation, initiator is a histone methyltransferase. But in principle, a similar system should work. Same logical design, with different catalytic functions propagating spread.
Home | The Team | The Project | Parts Submitted to the Registry | Modeling | Human Practices | Notebooks |
---|